The share value of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) rose 8.1% final week on Wall Road, giving a market cap of $23.5 billion. Because the inventory’s low-point in 2025 in April, the share value has risen over 60%.
The Israeli pharmaceutical firm, managed by CEO Richard Francis, will publish its third quarter monetary outcomes on Wednesday. In keeping with Yahoo Finance, analysts anticipate income to be much like the corresponding quarter of 2024 – $4.33 billion, and non-GAAP earnings per share of $0.67, down $0.02 from the corresponding quarter.
RELATED ARTICLES
Teva once more raises revenue steerage
Teva recycling debt after score improve
In keeping with the Wall Road Journal, out of 10 analysts protecting Teva inventory, 9 are optimistic and one is unfavourable, and the common value goal is $25.57 – a, 24.9% premium on the present share value. Final week, Jefferies analyst Dennis Ding revealed a evaluate forward of Teva’s report and addressed the problem of the IRA laws designed to decrease drug costs within the US, amongst different issues, within the pharmaceutical sector. Ding notes that traders will give attention to what Teva administration stated in regards to the impression on the drug Austedo (a branded drug for motion issues) and estimates that the corporate’s forecast for $2.5 billion in Austedo gross sales in 2027 will doubtless not change. This ieven although the value of the drug is predicted to fall.
Ding provides a “Purchase” suggestion for Teva’s inventory with a value goal of $24, a premium of 17.2%. On the similar time, Teva introduced that it has received an Excellence Award on the Economist Group’s EuroFinance Treasury convention, for the corporate’s money optimization and dealing capital administration.
Printed by Globes, Israel enterprise information – en.globes.co.il – on November 3, 2025.
© Copyright of Globes Writer Itonut (1983) Ltd., 2025.
